))
Highlights from ASCO Annual Meeting 2022
Manage episode 407440563 series 3560283
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.
Stephen M. Ansell, MD, PhD, discusses efforts to identify new upfront treatment regimens to help extend OS in patients with relapsed or refractory classical Hodgkin lymphoma. :25
Lorenzo Cohen, PhD, shares his thought on the impact of acupuncture regimens on xerostomia and patients’ quality of life. 5:26
Bradley J. Monk, MD, discusses the results of a study on the use of rucaparib monotherapy among women with advanced ovarian cancer 10:37
Christopher Manz, MD, MSHP, provides an overview of the results of the randomized PROStep trial, which assessed whether remote patient-reported symptoms and passive activity monitoring could improve patient-clinician communication about symptoms and functional status of patients with cancer. 18:09
Luke Maese, DO, discusses the results of the Children’s Oncology Group AALL1931 study, its rationale, the potential implications of the findings and the questions that must be addressed in future research. 21:04
Read the full coverage here:
https://www.healio.com/news/hematology-oncology/20220603/firstline-brentuximab-vedotin-regimen-extends-os-in-advanced-classical-hodgkin-lymphoma
https://www.healio.com/news/hematology-oncology/20220609/acupuncture-benefits-patients-with-radiationinduced-xerostomia
https://www.healio.com/news/hematology-oncology/20220606/rucaparib-shows-efficacy-as-firstline-maintenance-therapy-in-ovarian-cancer
https://www.healio.com/news/hematology-oncology/20220610/more-work-to-do-in-oncology-to-collect-useful-data-about-symptoms-functional-status
https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets
Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset
Source: Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer
Source: Modi S, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Disclosures:
Ansell reports research funding to his institution from ADC Therapeutics; Affimed Therapeutics, AI Therapeutics, Bristol Myers Squibb, Regeneron, Seagen and Trillium Therapeutics, and honoraria from Research to Practice and WebMD.
Cohen reports no relevant financial disclosures.
Monk reports relationships with Clovis Oncology, Merck, Roche/Genentech and several other pharmaceutical companies.
Manz reports no relevant financial disclosures.
Maese reports consultant and speakers bureau roles with Jazz Pharmaceuticals.
14 episoade
Distribuie
